Question to the Department of Health and Social Care:

To ask His Majesty's Government what assessment they have made of the effectiveness of Evusheld 2 in protecting clinically extremely vulnerable and immunocompromised people against COVID-19; and whether there are plans for it to be made available on the NHS.

The Medicines and Healthcare products Regulatory Agency (MHRA) has made no evaluation of Evusheld 2. Should such an application be received, the MHRA will review this for quality, safety and effectiveness and the overall benefit risk. The MHRA, together with independent advisory groups, continues to review the emerging body of evidence regarding potential medicines for the prevention or treatment of COVID-19.